DODeclan O'Dea

Declan O'Dea

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Declan O'Dea has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib

    by Seth A Wander, Neil O’brien, Lacey M Litchfield, Declan O’dea, Claudia Morato Guimaraes, Dennis J Slamon, Shom Goel

    Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4 and 6) are approved for the treatment of subsets of patients with hormone receptor positive (HR+) breast cancer (BC). In metastatic disease, strategies involving endocrine therapy combined with CDK4 and 6 inhibitors (CDK4 and 6i) improve clinical outcomes in HR+ BCs. CDK4 and 6i prevent retinoblastoma tumor suppressor protein phosphorylation, thereby blocking the transcription of E2F target genes, which in turn inhibits both mitogen and estrogen-mediated cell proliferation. In this review, we summarize preclinical data pertaining to the use of CDK4 and 6i in BC, with a particular focus on several of the unique chemical, pharmacologic, and mechanistic properties of abemaciclib. As research efforts elucidate the novel mechanisms underlying abemaciclib activity, potential new applications are being identified. For example, preclinical studies have demonstrated abemaciclib can exert antitumor activity against multiple tumor types and can cross the blood-brain barrier. Abemaciclib has also demonstrated distinct activity as a monotherapeutic in the treatment of BC. Accordingly, we also discuss how a greater understanding of mechanisms related to CDK4 and 6 blockade highlight abemaciclib’s unique in-class properties, and could pave new avenues for enhancing its therapeutic efficacy.


  • Raman spectroscopy for the preoperative diagnosis of thyroid cancer and its subtypes: An in vitro proof‐of‐concept study

    by Declan O'Dea, Massimo Bongiovanni, Gerasimos P. Sykiotis, Panos G. Ziros, Aidan D. Meade, Fiona M. Lyng, Alison Malkin

    Objective In 2016 there were an estimated 56,870 new cases of thyroid cancer (TC) in the United States. Fine needle aspiration cytology (FNAC) is the most safe, accurate and cost‐effective method for the initial investigation of thyroid nodules. FNAC is limited by the inability to accurately diagnose malignancy in follicular‐patterned lesions, and as a result 20% to 30% of cases under investigation for TC are classified as cytologically indeterminate, illustrating a problem with current FNAC procedure. Raman spectroscopy has shown promising results for the detection of many cancers however to date there has been no report on the performance of Raman spectroscopy on thyroid cytological samples. The aim of this study was to examine whether Raman spectroscopy could be used to correctly classify cell lines representing benign thyroid cells and various subtypes of TC. Methods A benign thyroid cell line and seven TC cell lines were prepared as ThinPrep® cytology slides and analysed with Raman spectroscopy. Principal components analysis (PCA) and linear discriminant analysis (LDA) were implemented to develop effective diagnostic algorithms for classification of Raman spectra of different TC subtypes. Results The spectral differences separating benign and TC cell lines were assigned to differences in the composition of nucleic acids, lipids, carbohydrates and protein in the benign and cancer cells. Good sensitivities (74 ‐ 85%), specificities (65 ‐ 93%) and diagnostic accuracies (71 – 88%) were achieved for the identification of TC. Conclusion These findings suggest that Raman spectroscopy has potential for preoperative TC diagnosis on FNAC samples.